Epizyme (EPZM) Misses Q1 EPS by 71c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Epizyme Announces First Quarter 2015 Financial Results and Provides Corporate Update
April 28, 2015 4:01 PM EDTReacquired global rights to EPZ-6438 from Eisai, gaining full control of development, manufacturing and commercialization outside of Japan Completed successful public offering of shares of common stock, raising $130.7 million before expenses, including the April exercise of the underwriters option to purchase additional shares Completed enrollment in 800 mg BID and 1600 mg BID dose expansion cohorts in ongoing EPZ-6438 Phase 1 study Updated data from the dose escalation cohorts of the ongoing Phase 1 study of EPZ-6438 to be presented at the International Conference on Malignant Lymphoma on June 20,... More
